Yao Ma

This paper develops a recombinant SARS-CoV-2 virus expressing reporter genes to track viral infection in wild-type mice, showing it can be used for vaccine and antiviral research without needing transgenic models.

This study identifies and characterizes a SARS-CoV-2 Mpro G23 deletion mutant resistant to ensitrelvir but not to nirmatrelvir or remdesivir.

This study shows that a combination of antibodies targeting both the SARS-CoV-2 spike protein's receptor binding domain (RBD) and stem helix (SH) domains prevents the emergence of viral escape mutants.

This study characterizes a broad-neutralizing influenza antibody, 1122A11, showing it neutralizes multiple NA subtypes and adapts to recent glycosylation changes in H3N2 viruses.

This paper develops an attenuated SARS-CoV-2 virus expressing nanoluciferase to identify and validate drug-resistant mutants to nirmatrelvir without using wild-type virus.

This study compares replication and pathogenicity of cattle-origin H5N1 influenza viruses in mammals and birds, finding higher replication efficiency and pathogenicity in human-adapted isolates.

This study develops a monoclonal antibody that broadly neutralizes multiple SARS-CoV-2 variants, including JN.1, and shows its protective efficacy in mice.